Ascendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results, Beats Expectations By $0.04 EPS

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) announced its earnings results on Wednesday. The biotechnology company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.25) by $0.04, MarketWatch Earnings reports. Ascendis Pharma A/S had a negative return on equity of 45.19% and a negative net margin of 5,015.63%. During the same period last year, the firm earned ($1.41) earnings per share.

Ascendis Pharma A/S stock opened at $80.01 on Friday. The firm has a market capitalization of $4.56 billion, a P/E ratio of -8.55 and a beta of 0.86. Ascendis Pharma A/S has a 1 year low of $61.58 and a 1 year high of $178.71. The business has a 50-day moving average of $106.85 and a 200-day moving average of $123.42.

Several institutional investors have recently bought and sold shares of ASND. Barclays PLC lifted its holdings in shares of Ascendis Pharma A/S by 117.5% during the 4th quarter. Barclays PLC now owns 627 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 4,218 shares in the last quarter. Guggenheim Capital LLC lifted its holdings in shares of Ascendis Pharma A/S by 42.9% during the 4th quarter. Guggenheim Capital LLC now owns 1,873 shares of the biotechnology company’s stock valued at $252,000 after purchasing an additional 562 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Ascendis Pharma A/S by 14.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 282 shares in the last quarter. Royal Bank of Canada lifted its stake in Ascendis Pharma A/S by 16.7% in the 3rd quarter. Royal Bank of Canada now owns 2,166 shares of the biotechnology company’s stock valued at $345,000 after acquiring an additional 310 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in Ascendis Pharma A/S by 25.4% in the 4th quarter. LPL Financial LLC now owns 2,736 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 555 shares in the last quarter.

ASND has been the subject of a number of research reports. Oppenheimer lowered their target price on Ascendis Pharma A/S from $166.00 to $154.00 in a research note on Thursday. Citigroup lowered their target price on Ascendis Pharma A/S from $187.00 to $158.00 in a research note on Thursday. Wedbush reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Monday, March 28th. Zacks Investment Research lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Monday, January 17th. Finally, Credit Suisse Group lowered their price objective on Ascendis Pharma A/S from $194.00 to $123.00 in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Buy” and a consensus target price of $163.58.

About Ascendis Pharma A/S (Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

See Also

Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.